Cart
sales@molnova.com
carfenazine
CAS No. 2622-30-2
carfenazine( —— )
Catalog No. M28924 CAS No. 2622-30-2
carfenazine targets the Dopamine receptor and is used for schizophrenia research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 183 | In Stock |
|
| 10MG | 275 | In Stock |
|
| 25MG | 471 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namecarfenazine
-
NoteResearch use only, not for human use.
-
Brief Descriptioncarfenazine targets the Dopamine receptor and is used for schizophrenia research.
-
Descriptioncarfenazine targets the Dopamine receptor and is used for schizophrenia research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorCalpain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2622-30-2
-
Formula Weight425.59
-
Molecular FormulaC24H31N3O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lon HK, et al. Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies. Clin Pharmacol Drug Dev. 2019 Apr. 8(3):290.
molnova catalog
related products
-
Fluphenazine decanoa...
Fluphenazine decanoate is dopamine D2 receptor blockeand is a long-acting phenothiazine neuroleptic that used to treat schizophrenia.
-
Seridopidine
Seridopidine (ACR343) is a modulator of dopaminergic activity that is used as an oral therapy for schizophrenia, Parkinson's disease, and Tourette's syndrome.
-
Bromocriptine mesyla...
Bromocriptine (CB-154) is a dopamine D2 receptor agonist (Ki=3 nM) and and various serotonin receptors, also inhibits the release of glutamate by reversing the glutamate GLT1 transporter.
